SAN DIEGO & FREMONT, Calif.–(BUSINESS WIRE)–Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between February 13, 2017 and September 30, 2020. Zosano Pharma is a clinical stage pharmaceutical company.
If you suffered a loss due to Zosano Pharma’s misconduct, click here.
Zosano Pharma Corporation (ZSAN) Misled Shareholders about its Lead Drug Candidate
According to the complaint, throughout the relevant period, Zosano touted the efficacy of its lead product candidate Qtrypta (M207), a formulation of zolmitriptan coated into the Company’s microneedle patch. Zosano’s drug trial for Qtrypta began in July 2016. In December 2019, Zosano submitted its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval for Qtrypta. On September 30, 2020, Zosano disclosed receipt of a discipline review letter from the FDA regarding its NDA for Qtrypta and stated that approval was not likely. Specifically, the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots and that patients exhibited unexpected high plasma concentrations of zolmitriptan. On this news, Zosano’s shares fell 57% per share on October 21, 2020.
If you purchased Zosano Pharma Corporation (ZSAN) securities between February 13, 2017 and September 30, 2020, you have until December 28, 2020, to ask the court to appoint you lead plaintiff for the class.
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Zosano Pharma Corporation settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.